Profil
Armin V.
Rath is the founder of Cytovia Therapeutics, Inc. He currently holds a job as Vice President-European Operations at Vector Therapeutics, Inc.
Postes actifs de Armin V. Rath
| Sociétés | Poste | Début |
|---|---|---|
Vector Therapeutics, Inc.
 Vector Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vector Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The firm engages in the acquisition, development, and commercialization of treatments for a variety of cancers, with a primary focus on leukemia. Its product portfolio consists initially of drugs targeting different stages and sub-types of Acute Myeloid Leukemia. The company was founded by Daniel Teper and is headquartered in New York, NY. | Directeur des opérations | - |
Cytovia Therapeutics, Inc.
 Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Vector Therapeutics, Inc.
Vector Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vector Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The firm engages in the acquisition, development, and commercialization of treatments for a variety of cancers, with a primary focus on leukemia. Its product portfolio consists initially of drugs targeting different stages and sub-types of Acute Myeloid Leukemia. The company was founded by Daniel Teper and is headquartered in New York, NY. | Health Technology |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
